Research ExplorerPublicationsImmune restoration in head and neck cancer patients after in...

Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.

Standard

Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. / Lang, Stephan; Tiwari, Sanjay; Andratschke, Michaela; Loehr, Iren; Lauffer, Lina; Bergmann, Christoph; Mack, Brigitte; Lebeau, Annette; Moosmann, Andreas; Whiteside, Theresa L; Zeidler, Reinhard.

In: CANCER IMMUNOL IMMUN, Vol. 56, No. 10, 10, 2007, p. 1645-1652.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lang, S, Tiwari, S, Andratschke, M, Loehr, I, Lauffer, L, Bergmann, C, Mack, B, Lebeau, A, Moosmann, A, Whiteside, TL & Zeidler, R 2007, 'Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.', CANCER IMMUNOL IMMUN, vol. 56, no. 10, 10, pp. 1645-1652. <http://www.ncbi.nlm.nih.gov/pubmed/17387473?dopt=Citation>

APA

Lang, S., Tiwari, S., Andratschke, M., Loehr, I., Lauffer, L., Bergmann, C., Mack, B., Lebeau, A., Moosmann, A., Whiteside, T. L., & Zeidler, R. (2007). Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. CANCER IMMUNOL IMMUN, 56(10), 1645-1652. [10]. http://www.ncbi.nlm.nih.gov/pubmed/17387473?dopt=Citation

Vancouver

Lang S, Tiwari S, Andratschke M, Loehr I, Lauffer L, Bergmann C et al. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. CANCER IMMUNOL IMMUN. 2007;56(10):1645-1652. 10.

Bibtex

@article{9875ff95177d4cb0bba0e45534575b52,
title = "Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.",
abstract = "PURPOSE: To determine the immunomodulatory effects of in vivo COX-2 inhibition on leukocyte infiltration and function in patients with head and neck cancer. EXPERIMENTAL DESIGN: Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks. Serum and tumor specimens were collected at the start of COX-2 inhibition (day 0) and again on the day of surgery (day 21). Adhesion to peripheral blood monocytes to ICAM-1 was examined. Percentages of tumor-infiltrating monocytes (CD68, CCR5) and lymphocytes (CCR5, CD4, CD8 and CD25) were determined by immunohistochemistry. RESULTS: Monocytes obtained from untreated cancer patients showed lower binding to ICAM-1 compared to monocytes of healthy donors but significantly regained adhesion affinity following incubation in sera of healthy donors. Conversely, sera of cancer patients inhibited adhesion of healthy donors' monocytes. Tumor monocyte adhesion to ICAM-1 was increased (P",
author = "Stephan Lang and Sanjay Tiwari and Michaela Andratschke and Iren Loehr and Lina Lauffer and Christoph Bergmann and Brigitte Mack and Annette Lebeau and Andreas Moosmann and Whiteside, {Theresa L} and Reinhard Zeidler",
year = "2007",
language = "Deutsch",
volume = "56",
pages = "1645--1652",
journal = "CANCER IMMUNOL IMMUN",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "10",

}

RIS

TY - JOUR

T1 - Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.

AU - Lang, Stephan

AU - Tiwari, Sanjay

AU - Andratschke, Michaela

AU - Loehr, Iren

AU - Lauffer, Lina

AU - Bergmann, Christoph

AU - Mack, Brigitte

AU - Lebeau, Annette

AU - Moosmann, Andreas

AU - Whiteside, Theresa L

AU - Zeidler, Reinhard

PY - 2007

Y1 - 2007

N2 - PURPOSE: To determine the immunomodulatory effects of in vivo COX-2 inhibition on leukocyte infiltration and function in patients with head and neck cancer. EXPERIMENTAL DESIGN: Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks. Serum and tumor specimens were collected at the start of COX-2 inhibition (day 0) and again on the day of surgery (day 21). Adhesion to peripheral blood monocytes to ICAM-1 was examined. Percentages of tumor-infiltrating monocytes (CD68, CCR5) and lymphocytes (CCR5, CD4, CD8 and CD25) were determined by immunohistochemistry. RESULTS: Monocytes obtained from untreated cancer patients showed lower binding to ICAM-1 compared to monocytes of healthy donors but significantly regained adhesion affinity following incubation in sera of healthy donors. Conversely, sera of cancer patients inhibited adhesion of healthy donors' monocytes. Tumor monocyte adhesion to ICAM-1 was increased (P

AB - PURPOSE: To determine the immunomodulatory effects of in vivo COX-2 inhibition on leukocyte infiltration and function in patients with head and neck cancer. EXPERIMENTAL DESIGN: Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks. Serum and tumor specimens were collected at the start of COX-2 inhibition (day 0) and again on the day of surgery (day 21). Adhesion to peripheral blood monocytes to ICAM-1 was examined. Percentages of tumor-infiltrating monocytes (CD68, CCR5) and lymphocytes (CCR5, CD4, CD8 and CD25) were determined by immunohistochemistry. RESULTS: Monocytes obtained from untreated cancer patients showed lower binding to ICAM-1 compared to monocytes of healthy donors but significantly regained adhesion affinity following incubation in sera of healthy donors. Conversely, sera of cancer patients inhibited adhesion of healthy donors' monocytes. Tumor monocyte adhesion to ICAM-1 was increased (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 56

SP - 1645

EP - 1652

JO - CANCER IMMUNOL IMMUN

JF - CANCER IMMUNOL IMMUN

SN - 0340-7004

IS - 10

M1 - 10

ER -